ISDA

Entry Detail

PDB ID:

8TXG

Keywords:

ONCOPROTEIN/INHIBITOR

Title:

Crystal structure of KRAS G12D in complex with GDP and compound 8

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2023-08-23

Release Date:

2023-11-08

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.50 Å

R-Value Free:

0.22

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

H 3 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:GTPase KRas
Mutations:G12D
Chain IDs:A
Chain Length:170
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P01116 Pfam ID:PF00071 EC:3.6.5.2

Ligand Molecules

GDP

VQT

Primary Citation

Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors.

Cheng, H, Li, P, Chen, P, Irimia, A, Bae, J.H, Brooun, A, Fagan, P, Lam, R, Lin, B, Zhang, J, Zhan, X, Wu, X, Xie, N, Chiang, G, Shoemaker, R, Vernier, J.M.Show

Acs Med.Chem.Lett. 14 1351 1357 (2023)

PMID: 37849557 DOI: 10.1021/acsmedchemlett.3c00245

Abstact

KRAS G12D mutation has been found in approximately 45% of pancreatic ductal adenocarcinoma (PDAC) cases, making it an attractive therapeutic target. Through structure-based drug design, a series of potent and selective KRAS G12D inhibitors were designed. The lead compound, ERAS-5024, inhibited ERK1/2 phosphorylation and cell proliferation in three-dimensional Cell-Titer Glo assays in AsPC-1 PDAC cells with single-digit nanomolar potency and caused tumor regression in the in vivo efficacy studies. We describe here the details of the design and synthesis program that led to the discovery of ERAS-5024.

Legend

Protein

Chemical

Disease

Primary Citation of related structures